Exchange: NASDAQ·Updated 03:58 PM EDT

DECA Denali Capital Acquisition Corp - Ordinary Shares - Class A

$0.55
$0.03
(5.17%)
Today
Mkt Cap$126.62M
Vol10,018.00

About DECA

Semnur Pharmaceuticals, Inc. engages in developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain. It offers the product, SP-102, a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe lumbosacral radicular pain. The company was founded in 2013 and is headquartered in Palo Alto, CA.
50

Neutral Sentiment

How do you feel about DECA?

Advertisement|Remove ads.